For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...

The peptide Palmitoyl-GHK (Pal-GHK) has garnered considerable attention in the scientific community due to its structural attributes and potential functional roles in biological research and cellular ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

The suit, which was filed on Wednesday, alleges the label "approved, published, and launched a campaign to create a viral hit out of a rap track" with Lamar's diss track Not Like Us, and that ...

The suit stems from the diss track “Not Like Us” by Kendrick Lamar, another UMG artist. Drake’s legal complaint also again accuses UMG of using bots on Spotify and other streaming platforms ...